Eisai (ESALY) and Biogen (BIIB) announced that an application for manufacturing and marketing approval for lecanemab, an anti-amyloid-beta protofibril antibody, in Japan has been designated for Priority Review by the Japanese Ministry of Health, Labour and Welfare. Priority Review in Japan is granted to new medicines recognized as having high medical utility for serious diseases, and once designated for Priority Review, the target total review period is shortened. In Japan, Eisai submitted the manufacturing and marketing approval for lecanemab to the Pharmaceuticals and Medical Devices Agency on January 16, 2023. This application is based on the results of the Phase III Clarity AD study and the Phase IIb clinical study, which demonstrated that lecanemab treatment showed a reduction of clinical decline in early AD.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- Lecanemab Receives Priority Review Status in Japan
- Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
- Eisai, Biogen: EMA accepts MAA for lecanemab for early Alzheimer’s disease
- Ionis confirms FDA to hold advisory committee meeting on tofersen NDA
- Biogen says FDA to convene advisory committee meeting for tofersen